Pluri

(NASDAQ) PSTI

Current PriceN/A

Market CapN/A

Since IPO (2003)-100%

5 Year-90%

1 Year-30%

1 Month+4%

Pluri Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$1.43M

Net Income (TTM)

$10.35M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

PSTI News

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Maxx ChatskoApr 28, 2020

Here's Why Pluristem Therapeutics Jumped Over 28% Today

Maxx ChatskoApr 24, 2020

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Leo SunNov 13, 2013

Why Pluristem Therapeutics Is Poised to Plunge

BRIAN PACAMPARAJan 16, 2013

3 Horrendous Health-Care Stocks This Week

Keith SpeightsDec 29, 2012

Are Short-Sellers Onto Something at Pluristem Therapeutics?

Rich DupreyNov 29, 2012

This Week in Biotech: Part 2

Sean WilliamsNov 10, 2012

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pluri

Industry

Biotechnology

Sector

Health Care

Employees

127

CEO

Yaky Yanay, CPA

Website

www.pluri-biotech.com

Headquarters

Haifa, 3508409, IL

PSTI Financials

Key Financial Metrics (TTM)

Gross Margin

36%

Operating Margin

-15%

Net Income Margin

-7%

Return on Equity

Return on Capital

Return on Assets

-62%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$654.00K

Operating Income

$23.33M

EBITDA

$23.33M

Operating Cash Flow

$18.21M

Capital Expenditure

$1.62M

Free Cash Flow

$19.83M

Cash & ST Invst.

$5.89M

Total Debt

$6.76M

Pluri Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$198.00K

+7.0%

Gross Profit

$86.00K

-22.5%

Gross Margin

43.43%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

153

N/A

Net Income

$6.87M

-472.1%

EBITDA

$6.63M

-27.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Net Cash

$2.17M

+60.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.14M

+25.3%

Short Term Debt

$712.00K

+19.7%

Return on Assets

-61.65%

N/A

Return on Invested Capital

1.38%

N/A

Free Cash Flow

$5.65M

-1364.4%

Operating Cash Flow

$5.21M

-813.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MGTAMagenta Therapeutics, Inc.

MGTAMagenta Therapeutics, Inc.$0.70-7.74%

RNTXRein Therapeutics Inc.

RNTXRein Therapeutics Inc.$1.27-12.07%

EYENEyenovia, Inc.

EYENEyenovia, Inc.$7.56+3.99%

STSASatsuma Pharmaceuticals, Inc.

STSASatsuma Pharmaceuticals, Inc.$1.10+0.00%

LUMOLumos Pharma, Inc.

LUMOLumos Pharma, Inc.$4.34+0.00%

RENBLunai Bioworks Inc.

RENBLunai Bioworks Inc.$1.42+0.00%

GRNAGreenLight Biosciences Holdings

GRNAGreenLight Biosciences Holdings$0.30-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.53-0.15%

NOKNokia

NOKNokia$12.46+0.10%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.67+0.39%

POETPoet Technologies

POETPoet Technologies$6.60-0.18%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.93-0.02%

Questions About PSTI

What is the current price of Pluri?

Pluri is trading at N/A per share.

What is the 52-week range for Pluri?

Over the past 52 weeks, Pluri has traded between N/A and N/A.

How much debt does Pluri have?

As of the most recent reporting period, Pluri reported total debt of $34.64M.

How much cash does Pluri have on hand?

Pluri reported $4.91M in cash and cash equivalents in its most recent financial results.

What is Pluri’s dividend yield?

Pluri does not currently have a dividend yield.

Pluri

Pluri Financials at a Glance

PSTI News

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

Here's Why Pluristem Therapeutics Jumped Over 28% Today

Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sangamo Biosciences, Inc.

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Why Pluristem Therapeutics Is Poised to Plunge

3 Horrendous Health-Care Stocks This Week

Are Short-Sellers Onto Something at Pluristem Therapeutics?

This Week in Biotech: Part 2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Pluri

PSTI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Pluri Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PSTI

What is the current price of Pluri?

What is the 52-week range for Pluri?

How much debt does Pluri have?

How much cash does Pluri have on hand?

What is Pluri’s dividend yield?

Premium Investing Services